Abstract
Methylene blue is used for bacterial staining in microbiology and as an antidote drug in medicine. In this study, we aimed to investigate the antimicrobial effects of methylene blue against Mycobacterium tuberculosis complex clinical isolates. Seventeen stored M. tuberculosis complex clinical isolates were included in the study. The isolates were inoculated into Mycobacteria Growth Indicator Tubes and incubated in Automated Mycobacterial Detection System. Mycobacteria Growth Indicator tubes containing methylene blue at critical concentrations of 0.2, 2, 20, 1000 µg ml-1 and control tube were prepared. Antimicrobial susceptibility testing was performed using Automated Mycobacterial Detection System which is gold standard for second line anti-tuberculosis drug testing. At the end of the study, six clinical isolates were susceptible to methylene blue at all critical concentrations. Five isolates were susceptible to only 1000 µg ml-1 methylene blue. Three isolates were susceptible to 1000 and 20 µg ml-1 methylene blue. Susceptibility rate was found as 94% when the critical proportion was accepted 400 GU (1/100 of control). Significant relationship was observed between the administered methylene blue concentrations and bacterial survival rate in statistical analysis. We conclude that methylene blue may become a potential anti-tuberculosis agent due to its well-known side effects and dosing regimens.
Highlights
Methylene blue (MB) is used for bacterial staining, and as an antidote drug
In this study we aimed to investigate the inhibitory effect of MB compound against M. tuberculosis complex clinical isolates in our university hospital
A total of 17 M. tuberculosis complex clinical isolates showing different antibiogram patterns were included in the study
Summary
We aimed to investigate the antimicrobial effects of MB against Mycobacterium tuberculosis complex clinical isolates. Mycobacterium tuberculosis complex species share 99.9% sequence identity and probably evolved from a single clone [1, 2]. The species Mycobacterium tuberculosis causes the vast majority of human tuberculosis (TB) worldwide. The Mycobacterium africanum species causes human TB in West Africa, where it accounts for up to 50% of cases [1, 3]. An estimated 10 million people had TB in 2018. There were an estimated 1.2 million TB deaths among HIVnegative people in the year 2018. The latest treatment outcome data for new cases of TB show a global treatment success rate of 85% in 2017, an increase of 81% since 2016 [4]
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have